106 related articles for article (PubMed ID: 25863215)
1. A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease Therapies.
Sinha SR; Nguyen LP; Inayathullah M; Malkovskiy A; Habte F; Rajadas J; Habtezion A
Gastroenterology; 2015 Jul; 149(1):52-55.e2. PubMed ID: 25863215
[TBL] [Abstract][Full Text] [Related]
2. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.
Lu F; Fernandes SM; Davis AE
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G878-83. PubMed ID: 20338925
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Sann H; Erichsen Jv; Hessmann M; Pahl A; Hoffmeyer A
Life Sci; 2013 Apr; 92(12):708-18. PubMed ID: 23399699
[TBL] [Abstract][Full Text] [Related]
4. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Klotz U; Schwab M
Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
[TBL] [Abstract][Full Text] [Related]
5. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
[TBL] [Abstract][Full Text] [Related]
6. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
[TBL] [Abstract][Full Text] [Related]
7. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
9. The application and relevance of ex vivo culture systems for assessment of IBD treatment in murine models of colitis.
Fritsch Fredin M; Vidal A; Utkovic H; Götlind YY; Willén R; Jansson L; Hultgren Hörnquist E; Melgar S
Pharmacol Res; 2008; 58(3-4):222-31. PubMed ID: 18812224
[TBL] [Abstract][Full Text] [Related]
10. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
11. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.
De Vry CG; Prasad S; Komuves L; Lorenzana C; Parham C; Le T; Adda S; Hoffman J; Kahoud N; Garlapati R; Shyamsundar R; Mai K; Zhang J; Muchamuel T; Dajee M; Schryver B; McEvoy LM; Ehrhardt RO
Gut; 2007 Apr; 56(4):524-33. PubMed ID: 16950831
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of piperine on dextran sulfate sodium induced inflammatory bowel disease and its relation with pregnane X receptor activation.
Hu D; Wang Y; Chen Z; Ma Z; You Q; Zhang X; Liang Q; Tan H; Xiao C; Tang X; Gao Y
J Ethnopharmacol; 2015 Jul; 169():109-23. PubMed ID: 25907981
[TBL] [Abstract][Full Text] [Related]
13. Comparison of experimental mouse models of inflammatory bowel disease.
Oh SY; Cho KA; Kang JL; Kim KH; Woo SY
Int J Mol Med; 2014 Feb; 33(2):333-40. PubMed ID: 24285285
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
[TBL] [Abstract][Full Text] [Related]
15. Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice.
Sha T; Igaki K; Yamasaki M; Watanabe T; Tsuchimori N
Int Immunopharmacol; 2013 Jan; 15(1):23-9. PubMed ID: 23142502
[TBL] [Abstract][Full Text] [Related]
16. Fermented barley and soybean (BS) mixture enhances intestinal barrier function in dextran sulfate sodium (DSS)-induced colitis mouse model.
Woo JK; Choi S; Kang JH; Kim DE; Hurh BS; Jeon JE; Kim SY; Oh SH
BMC Complement Altern Med; 2016 Dec; 16(1):498. PubMed ID: 27912750
[TBL] [Abstract][Full Text] [Related]
17. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model.
Ghia JE; Blennerhassett P; Kumar-Ondiveeran H; Verdu EF; Collins SM
Gastroenterology; 2006 Oct; 131(4):1122-30. PubMed ID: 17030182
[TBL] [Abstract][Full Text] [Related]
18. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease.
Verlinden L; Leyssens C; Beullens I; Marcelis S; Mathieu C; De Clercq P; Verstuyf A
J Steroid Biochem Mol Biol; 2013 Jul; 136():107-11. PubMed ID: 23000190
[TBL] [Abstract][Full Text] [Related]
20. Exploration of target molecules for molecular imaging of inflammatory bowel disease.
Higashikawa K; Akada N; Yagi K; Watanabe K; Kamino S; Kanayama Y; Hiromura M; Enomoto S
Biochem Biophys Res Commun; 2011 Jul; 410(3):416-21. PubMed ID: 21672527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
